Question 1

What is Vesugen and what is its sequence?

Accepted Answer

Vesugen is the synthetic tripeptide Lys-Glu-Asp (KED), one of the 'short peptide bioregulators' developed by Vladimir Khavinson's group and studied in research framing for the vascular wall/endothelium and cellular aging. It is a Research Use Only material and is not an approved drug.

Question 2

What does the published research actually show?

Accepted Answer

According to PubMed-indexed studies, most evidence is in vitro. In endothelial cell cultures KED was reported to normalize endothelin-1 and increase sirtuin-1 (PMID 28539025) and to stimulate the proliferation marker Ki-67 with a proposed gene-promoter interaction shown by molecular docking (PMID 25051766). Broader cell-aging and neuronal-differentiation effects have also been reported (e.g., PMIDs 32399807, 30791821, 39518916). Human data are limited to small, uncontrolled studies.

Question 3

Is there any human research?

Accepted Answer

Yes, but it is limited. A few small Russian studies, frequently combining Vesugen with the peptide Pinealon, reported changes in 'biological age' measures (PMIDs 28539017, 26390612), and one monotherapy study in older men with vasculogenic erectile dysfunction reported changes in Doppler-measured arterial blood flow (PMID 25051774). These were small, non-randomized, and not placebo-controlled, so they are hypothesis-generating rather than confirmatory and should not be read as evidence of clinical benefit.

Question 4

How strong and independent is the evidence?

Accepted Answer

It is weak and not independently established. Nearly all studies originate from a single research network (Khavinson and collaborators), many human reports appear in Russian-language journals, several human studies tested peptide combinations rather than KED alone, and there is little independent replication and no registered randomized controlled trial.

Question 5

What is the proposed mechanism?

Accepted Answer

The authors propose an epigenetic/gene-regulatory model in which KED interacts with specific gene-promoter sequences to modulate expression of vascular- and aging-related genes (for example, endothelin-1, sirtuin-1, and the Ki-67/MKI67 proliferation gene), rather than acting through a classical receptor (PMIDs 28539025, 25051766, 24909721). This mechanism is largely inferred from in vitro work and molecular docking and remains to be confirmed.

Question 6

Were any unfavorable effects observed in the research?

Accepted Answer

In one small human geroprotection study, the Vesugen + Pinealon combination was associated with prooxidant activity (by chemiluminescence) and a reduction in circulating CD34+ hematopoietic progenitor cells alongside the reported anabolic effects (PMID 26390612). This is a single small study; the overall profile of observed effects in research is not well characterized, and on this platform Vesugen is handled strictly as a Research Use Only material.

Question 7

Is there an established dose?

Accepted Answer

No human dose is established, and none is provided here. Research-reported amounts and schedules vary across the limited primary literature, which is not standardized; for any study-design questions, consult the specific protocol reference rather than this summary. This is not medical advice, and Vesugen is Research Use Only.

Phase	Reference amount	Units / volume
Week 1	500 mcg (0.5 mg)	7.5 units (0.075 mL)
Week 2	1000 mcg (1.0 mg)	15 units (0.15 mL)
Week 3	1500 mcg (1.5 mg)	22.5 units (0.225 mL)
Weeks 4–8+	1500–2000 mcg (1.5–2.0 mg)	22.5–30 units (0.225–0.30 mL)

Vesugen (Lys-Glu-Asp).

Calculated-volume support unavailable

Cited protocol & reconstitution guide